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Abstract
Background: Dengue is a potentially fatal acute febrile illness (AFI) caused by four mosquito-transmitted dengue viruses
(DENV-1–4) that are endemic in Puerto Rico. In January 2010, the number of suspected dengue cases reported to the
passive dengue surveillance system exceeded the epidemic threshold and an epidemic was declared soon after.
Methodology/Principal Findings: To characterize the epidemic, surveillance and laboratory diagnostic data were compiled. A
suspected case was a dengue-like AFI in a person reported by a health care provider with or without a specimen submitted for
diagnostic testing. Laboratory-positive cases had: (i) DENV nucleic acid detected by reverse transcriptase-polymerase chain
reaction (RT-PCR) in an acute serum specimen; (ii) anti-DENV IgM antibody detected by ELISA in any serum specimen; or (iii)
DENV antigen or nucleic acid detected in an autopsy-tissue specimen. In 2010, a total of 26,766 suspected dengue cases (7.2
per 1,000 residents) were identified, of which 46.6% were laboratory-positive. Of 7,426 RT-PCR-positive specimens, DENV-1
(69.0%) and DENV-4 (23.6%) were detected more frequently than DENV-2 (7.3%) and DENV-3 (,0.1%). Nearly half (47.1%) of all
laboratory-positive cases were adults, 49.7% had dengue with warning signs, 11.1% had severe dengue, and 40 died.
Approximately 21% of cases were primary DENV infections, and 1–4 year olds were the only age group for which primary
infection was more common than secondary. Individuals infected with DENV-1 were 4.2 (95% confidence interval [CI]: 1.7–9.8)
and 4.0 (95% CI: 2.4–6.5) times more likely to have primary infection than those infected with DENV-2 or -4, respectively.
Conclusions/Significance: This epidemic was long in duration and yielded the highest incidence of reported dengue cases
and deaths since surveillance began in Puerto Rico in the late 1960’s. This epidemic re-emphasizes the need for more
effective primary prevention interventions to reduce the morbidity and mortality of dengue.
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Introduction
Dengue virus (DENV) transmission is endemic throughout most
of the tropics and sub-tropics and is estimated to result in ,50
million symptomatic infections and ,20,000 deaths each year [1,2].
Infection with any DENV can result in dengue, an illness
characterized by fever, headache, retro-orbital eye pain, myalgia
and rash [2]. In some cases, dengue can progress to severe dengue
[2], which includes dengue hemorrhagic fever (DHF) and dengue
shock syndrome (DSS) [3] and is characterized by thrombocytope-
nia, increased vascular permeability with plasma leakage, severe
organ involvement, and/or clinically significant bleeding [2].
Supportive care with appropriate intravascular volume repletion
has been shown to lower mortality associated with severe dengue [2].
The four related but serotypically distinct DENV-types, DENV-
1, -2, -3 and -4, are transmitted by Aedes aegypti or Ae. albopictus
mosquitoes [4,5]. Following infection, individuals develop short-
lived, heterotypic immunity and long-lived, type-specific immunity
[6]. Primary infection is an individual’s first DENV infection, and
secondary infection is any subsequent infection with a DENV-type
different from the first. Severe dengue is more common upon
secondary infection [2,7] and may be affected by the order in
which an individual is infected with the respective DENV-types
[2,8]. Thus, increases in the force of DENV infection can result in
a decrease in the age of primary and secondary infection [2]. Both
local patterns of circulation of the four DENV-types and force of
infection can influence the age groups most affected by dengue
and severe dengue.
The unincorporated United States territory of Puerto Rico is
composed of 78 municipalities, an area of 3,515 square miles, and
a population of 3,725,789 [9]. The demographics of Puerto Rico
are similar to the United States as median age is 36 years and
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78.6% are white, although 99% are self-described Hispanic [9].
Since the mid-1990’s the health care system in Puerto Rico has
included both public and private health care services, and dengue
has been a reportable condition for several decades. Ae. aegypti is
the predominant DENV vector on the island.
Dengue was first described in Puerto Rico in 1915 [10] and
outbreaks have been recognized since 1963 [11,12]. DHF was first
reported in 1975 [13,14], all four DENV-types have been
identified on the island since 1982 [15,16], and the first confirmed
dengue-related death was reported in 1986 [17]. Recent epidemics
were detected in 1994–1995, 1998 and 2007, with 24,700 [18],
17,000 [19] and 10,508 [20] reported suspect cases, respectively
(Table S1). During both epidemic and non-epidemic periods, 10–
19 year olds have been the most affected age group for several
decades.
In the present investigation, we describe a dengue epidemic that
occurred in 2010, including differences in the epidemiology of




A retrospective analysis of suspected dengue cases reported to
surveillance systems was performed to: 1) describe the epidemi-
ology of the 2010 dengue epidemic, including disease severity; 2)
determine the proportion of primary and secondary DENV
infections, and the molecular epidemiology of the DENVs
responsible for the epidemic; and 3) describe relationships between
demographic variables (e.g. age, sex, municipality of residence)
and characteristics of illness (e.g. infecting DENV-type, severity of
illness). This investigation underwent institutional review at CDC
and was determined to be public health practice and not research,
including the post-hoc determinations of DENV molecular
epidemiology and primary/secondary infection rates in reported
cases; as such, Institutional Review Board approval was not
required.
Data sources
Surveillance data from five sources were used to identify cases.
First, Centers for Disease Control and Prevention Dengue Branch
(CDC-DB) and Puerto Rico Department of Health (PRDH) jointly
operate the island-wide Passive Dengue Surveillance System
(PDSS) that requires an acute serum specimen and completion
of a Dengue Case Investigation Form (DCIF) (cdc.gov/dengue/
resources/dengueCaseReports/DCIF_English.pdf) for case re-
porting and diagnostic testing. Second, the Enhanced Dengue
Surveillance System (EDSS) operates solely in the municipalities of
Patillas and Guayama and utilizes an on-site nurse epidemiologist
to encourage case reporting and patient follow-up to obtain a
convalescent serum specimen [21]. Third, identification of fatal
dengue cases is conducted via PDSS and EDSS [22], and
enhanced fatal case surveillance was initiated in January 2010 in
collaboration with the Instituto de Ciencias Forenses de Puerto
Rico, which obtains blood and tissue specimens at autopsy from
suspected dengue-related deaths. Fourth, PRDH operates the
Notifiable Diseases Surveillance System (NDSS) wherein suspected
dengue cases are reported without diagnostic testing at CDC-DB.
Last, in addition to dengue diagnostic testing performed at CDC-
DB for PDSS and EDSS, testing is performed by two private
diagnostic laboratories outside of Puerto Rico according to their
internal protocols [23]. Diagnostic test results from these
laboratories and patient data, including sex, age, and date of
illness onset (if unavailable, specimen collection date was used
instead), were entered into an independent database. Deduplica-
tion of individuals reported to more than one data source was
achieved by matching records on name and date of birth and
consolidation into a single case if two or more reports from any
data source had symptom onset dates within 14 days of each other.
As case-patients’ travel history is not well captured via the
surveillance systems used in this investigation, reported cases may
represent both locally-acquired as well as travel-associated cases.
Dengue diagnostic testing
All diagnostic testing was performed at CDC-DB for serum
specimens received through PDSS or EDSS using the following
algorithm: acute specimens (collected #5 days after symptom
onset) were tested by DENV-type-specific real-time reverse-
transcriptase-polymerase chain reaction (RT-PCR) [24] adapted
for high throughput using MDX-10 Universal and M48 systems
(Qiagen, Valencia, CA); acute specimens collected 5 days after
symptom onset and all convalescent specimens (collected $6 days
after symptom onset) were tested for the presence of anti-DENV
immunoglobulin M (IgM) antibody with an antibody-capture
enzyme-linked immunosorbent assay (MAC ELISA) and a cut-off
value of the OD450 of the specimen versus that of the negative
control (ie. P/N ratio ) $2.0 [25,26]. All serum specimens from
fatal cases were tested by both RT-PCR and MAC ELISA. Tissue
specimens were tested at CDC Infectious Diseases Pathology
Branch in Atlanta, GA by immunohistochemistry (IHC) [27] and
flavivirus-specific RT-PCR [28] followed by sequencing.
Definitions
A suspected dengue case was a dengue-like illness in a person in
Puerto Rico whose health care provider: 1) submitted a DCIF and
serum or tissue specimen to CDC-DB for dengue diagnostic
testing; 2) submitted a serum specimen to a private laboratory for
dengue diagnostic testing; or 3) reported the case via NDSS.
A laboratory-positive case was a suspected dengue case that met
the following criteria for current (criteria 1 and 2) or recent
(criterion 3) DENV infection: 1) detection of DENV nucleic acid
in a serum or tissue specimen; 2) detection of DENV antigen in a
Author Summary
Dengue is a potentially fatal acute febrile illness that is
endemic throughout the tropics and sub-tropics. Dengue
has been endemic in Puerto Rico for several decades and
recent epidemics occurred in 1994–5, 1998 and 2007. In
January 2010, dengue surveillance indicated that an
epidemic had begun. The epidemic peaked in early August
and ended in December with a total of 26,766 suspected
dengue cases identified, of which 128 were fatal. The 2010
epidemic was one of the longest in Puerto Rico history and
resulted in the greatest number of cases and deaths ever
detected. We analyzed the epidemiologic and immuno-
logic characteristics of laboratory-confirmed dengue cases
and age group-specific attack rates, and determined the
frequency of first DENV infection and DENV-types among
persons experiencing their first infection. This analysis
indicated that 10–19 year-olds were most affected during
the epidemic, and that DENV-1 was roughly four times
more likely to be associated with clinically apparent illness
upon first DENV infection than were DENV-2 or -4. The
2010 dengue epidemic demonstrated the heavy burden of
illness due to dengue in Puerto Rico, re-emphasizing the
critical need for effective primary prevention tools to
reduce the morbidity and mortality due to dengue
worldwide.
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tissue specimen; or 3) detection of anti-DENV IgM antibody in a
serum specimen.
A laboratory-negative case was a suspected dengue case with: 1)
no anti-DENV IgM antibody detected in a convalescent specimen;
or 2) no DENV nucleic acid or antigen detected in a fatal case with
only a tissue specimen submitted.
A laboratory-indeterminate case was a suspected dengue case
with no DENV nucleic acid or anti-DENV IgM antibody detected
in an acute specimen with no convalescent specimen available for
testing.
Dengue with warning signs and severe dengue were defined
according to 2009 WHO clinical guidelines [2]; dengue, DHF and
DSS were defined according to 1997 WHO clinical guidelines [3].
Primary and secondary DENV infections
A representative sample of all RT-PCR-positive cases reported
to PDSS or EDSS with illness onset between January 1 and
December 31, 2010 was selected to determine the rates of primary
and secondary DENV infection. Cases were stratified by age
group with optimal allocation to allow for comparison between
age groups, and further allocated to reflect the proportion of
DENV-types that occurred during 2010 to allow for comparison
between DENV-types and age groups. Sample size was calculated
using an estimate of the proportion of secondary infections by age
group based on data from the 2007 dengue epidemic [20], an
error of 20%, 95% significance, and an expected 20% of
specimens having insufficient specimen volume remaining for
testing to be completed. Of the 1,000 selected cases, 818 had
sufficient specimen volume and were tested at a dilution of 1:100
for the presence of anti-DENV IgG antibody by ELISA using
DENV-1–4 antigen and a cut-off value of OD450$0.15 [29,30]. A
secondary DENV infection was defined by detection of anti-
DENV IgG antibody in an acute specimen, and a primary DENV
infection by lack of anti-DENV IgG antibody detection in an acute
specimen.
Sequencing and phylogenetic analysis
Serum specimens with DENV-1 (n = 7), DENV-2 (n = 2) or
DENV-4 (n = 4) detected by RT-PCR were randomly selected
from municipalities with the highest incidence of the respective
DENV-type and inoculated into cultured C6/36 cells; the
presence of virus was confirmed by RT-PCR and indirect
immunofluorescence [31]. Isolates were further propagated and
viral RNA was extracted from culture supernatants using the M48
BioRobot System (Qiagen; Valencia, CA). The envelope glyco-
protein (E) gene was amplified and sequenced; sequence data were
restricted to the E gene open reading frame (1,485 basepairs).
Multiple sequence alignment was performed using MUSCLE
available in MEGA 5 (megasoftware.net) and GTR+C+I4 was
selected as the best nucleotide substitution model as determined by
MODELTEST v3.7. Genetic relatedness was inferred and
represented with phylogenetic trees using the maximum likelihood
method in MEGA 5. MCMC was run in BEAST v1.6.1
(beast.bio.ed.ac.uk) under Bayesian skyline prior, constructed in
TreeAnnotator found in the same BEAST package, and visualized
in FigTree v1.3. Both trees rendered almost identical tree
topologies, therefore confirming genetic relatedness. Evolutionary
distances were corroborated by pairwise alignment in BioEdit
v7.1.3 and E gene sequences from GenBank were included in the
phylogenetic tree to support tree topology by currently circulating
genotype. Tree topology was supported by bootstrapping with
1,000 replicates. Genotypes were referred to by previously
described nomenclature [32,33].
Statistical analyses
The frequencies of clinical, demographic and laboratory data
were calculated by performing descriptive analyses of all suspected
dengue cases identified in 2010. Rates of suspected dengue and
laboratory-positive cases were calculated using population denom-
inators obtained from the 2010 United States Census [9].
Statistical differences in proportions were tested by applying the
Chi-squared test and Fisher’s exact test when applicable. Unless
otherwise noted, relative risk ratios were used to calculate all
differences between effect sizes. All data analyses were conducted
using SAS 9.2 (SAS Institute Inc., Cary, NC), graphs were
produced in Microsoft Excel (Microsoft Corp., Redmond, WA),
and maps were created using ArcView (ESRI, Redlands, CA).
Results
Suspected cases
We identified 26,766 suspected dengue cases with illness onset
between January 1 and December 31, 2010 (7.2 suspected dengue
cases per 1,000 residents). Of these, 22,496 (84.0%) were reported
to PDSS, 1,846 (6.9%) were identified though diagnostic testing at
a private laboratory, 1,304 (4.9%) were reported to NDSS, and
1,120 (4.2%) were reported to EDSS (Fig. S1). Suspected dengue
cases exceeded the PDSS epidemic threshold in the first week of
2010, increased steeply in week 20 (May 14–20), and peaked at
1,157 in week 32 (August 6–12) (Fig. 1). Suspected dengue cases
slowly declined thereafter and returned to below the historic
average in mid-December.
Of all suspected dengue cases, 25,852 (96.6%) had a specimen
tested for evidence of DENV infection, of which 25,246 (97.7%)
were tested by CDC-DB and the remainder by a private
laboratory; paired specimens were available for 1,996 (7.5%)
cases. Of all cases with a specimen tested, 3,664 (14.2%) were
laboratory-negative, 10,140 (39.2%) were laboratory-indetermi-
nate, and 12,048 (46.6%) were laboratory-positive (3.2 laboratory-
positive cases per 1,000 residents). The median weekly proportion
of cases that tested laboratory-positive was 48.3%, and was highest
(64.5%) in week 24 (June 11–17) and lowest (11.1%) in week 53
(December 31).
Laboratory-positive cases
Laboratory-positive case-patients resided in all 78 municipalities
of Puerto Rico (Fig. 2A), and the median rate of laboratory-
positive cases by municipality was 2.68 per 1,000 residents. Rates
were the highest in the municipality of Patillas (16.34 cases per
1,000 residents), the southeastern municipality where the EDSS
site is located [21], and lowest in Aibonito (0.12 cases per 1,000
residents) in the mountainous center of Puerto Rico. Of 7,426 RT-
PCR-positive cases, DENV-1 was detected in 5,126 (69.0%) and
incidence was highest in the southeast (Fig. 2B). DENV-2 was
detected in 545 (7.3%) cases primarily in the west (Fig. 2C),
whereas DENV-4 was detected in 1,757 (23.7%) cases and
incidence was highest in south-central and northwestern Puerto
Rico (Fig. 2D). DENV-3 was detected in just two (,0.1%) cases in
early 2010.
The age distribution of laboratory-positive cases was signifi-
cantly different from suspected dengue cases only for case-patients
between 30 and 69 years of age (Fisher’s exact, p#0.04). The
median age of laboratory-positive case-patients was 18 years
(Table 1). The most affected age group was 10–14 year olds (7.8
cases per 1,000 individuals), followed by 15–19 year olds (7.4 cases
per 1,000 individuals) (Fig. 3A). Five-to-nine year olds were the
next most affected age group followed by individuals ,1 year of
age (4.6 and 4.1 cases per 1,000 individuals, respectively).
A Dengue Epidemic in Puerto Rico, 2010
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Individuals 50–59 years of age were the least affected age group
(1.7 cases per 1,000 individuals).
The distribution of RT-PCR-positives cases among age groups was
not significantly different from that of laboratory-positive cases
(Fisher’s exact, p.0.05) except for the 50–59 year-old age group, for
which serum specimens were collected later (median: 6 days post-
illness onset [DPO]) than all other age groups (median: 4 DPO)
(Fisher’s exact, p = 0.04) and thus tested less frequently by RT-PCR.
Despite this, the distribution of DENV-types was not consistent
among age groups (Fig. 3B). The strong majority (89.3%) of RT-
PCR-positive cases in individuals 1–4 years of age were due to
infection with DENV-1, whereas 8.1% and 2.6% were due to
infection with DENV-4 and -2, respectively. The percent of infections
due to DENV-1 decreased and those due to DENV-4 increased with
age until a plateau of approximately 60% DENV-1, 30% DENV-4
and 10% DENV-2 was reached in the 20–29 year old age group.
Figure 1. Epidemic curve of suspected dengue cases by week of illness onset, Puerto Rico, 2010. Surveillance data from cases reported
via the Passive Dengue Surveillance System, Enhanced Dengue Surveillance System, Notifiable Diseases Surveillance System, or private laboratory
dengue diagnostic test results were compiled and grouped by diagnostic test result as indicated.
doi:10.1371/journal.pntd.0002159.g001
Figure 2. Rates of laboratory-positive cases by municipality, Puerto Rico, 2010. Rates were calculated by dividing case numbers by
municipality-specific populations and grouping by quintile of rate of all laboratory-positive cases. Rates shown are: (A) All laboratory-positive cases;
or laboratory-positive cases with DENV-1 (B), DENV-2 (C), or DENV-4 (D) detected by RT-PCR.
doi:10.1371/journal.pntd.0002159.g002
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Primary and secondary DENV infections
From the sample of 818 RT-PCR-positive specimens tested for
primary versus secondary DENV infection, 169 (20.7%) were
primary and 649 (79.3%) were secondary. The median age of
individuals experiencing primary infection was 14 years, compared
to 23 years for individuals experiencing secondary infection.
Eighty-one percent of individuals 1–4 years of age had primary
infection and were the only age group for which primary infection
was significantly more common than secondary (p = 0.003)
(Figure 3C). More than 89% of infections in all adult age groups
(i.e. age $20 years) were secondary. The frequency with which
anti-DENV IgG antibody was detected in specimens taken from
infants was likely due to the presence of maternal antibody [2].
Whereas 28.5% of all DENV-1 infections were primary,
significantly fewer DENV-2 (6.8%) and DENV-4 (7.1%) cases
were primary infections (p,0.0001) (Table 2). Calculation of
relative risk ratios (RR) indicated that individuals infected with
DENV-1 were 4.2 and 4.0 times more likely to be experiencing
primary infection than were individuals infected with DENV-2 or
-4, respectively (Table 2).
Molecular epidemiology
Sequencing and phylogenetic analyses of randomly selected
DENV isolates showed that DENV-1 belonged to the American-
African genotype (genotype V [34]), but to a clade distinct from
virus isolated during the 1998 Puerto Rico epidemic (Fig. 4A).
Available sequence data suggest that close ascendants of the 2010
DENV-1 clade had been circulating in Puerto Rico and the
Caribbean since at least 2006 (Fig. 4A). DENV-2 sequencing
indicated that the virus belongs to clade 1B of the American-Asian
genotype (genotype IIIb [35]) (Fig. 4B), which is composed of
DENV strains endemic to Puerto Rico [36]. DENV-4 belonged to
the Indonesian genotype (genotype II [37]), but was distinct from
virus isolated in 1998 (Fig. 4C). Viruses closely-related to the
DENV-4 isolated in 2010 were first detected in Puerto Rico in
2004 (Fig. 4C).
Disease severity
Of 12,048 laboratory-positive cases, 31.5% had at least one
hemorrhagic manifestation and sufficient clinical data was
provided to classify 74.0% as dengue and 2.4% as DHF
(Table 1). Nearly half (49.7%) of all laboratory-positive cases
had dengue with at least one warning sign, and 11.1% had severe
dengue. Of 128 suspected dengue deaths, 40 (31.3%) were
laboratory-positive cases. While adults represented nearly half of
laboratory-positive cases with dengue (47.1%), dengue with
warning signs (44.6%), and severe dengue (49.7%), they accounted
for nearly all (92.5%) fatal dengue cases. Laboratory-positive
severe and fatal dengue occurred at a rate of 0.36 and 0.01 cases
per 1,000 residents, respectively; laboratory-positive fatal dengue
cases occurred at a rate of 30.0 per 1,000 severe dengue cases.
From the sample of cases for which primary and secondary DENV
infection status was determined, secondary infection was identified
in 102 (87.9%) case-patients with severe dengue and 547 (77.9%)
case-patients without severe dengue (RR = 1.2; 95% CI = 1.1–1.2).
Case-patients with DHF were more likely to have been infected
with DENV-4 than DENV-1, and those with severe dengue were
more likely to have been infected with DENV-4 than DENV-1 or -
2 (Table 2). There was no significant difference between infection
with DENV-1, -2 or -4 and likelihood of being a fatal case.
Discussion
In 2010, Puerto Rico experienced the largest and longest
dengue epidemic ever documented on the island. In total, more
than 12,000 individuals had laboratory-confirmed dengue, of
which more than 1,300 experienced severe dengue and 40 died.
The most common DENV identified was DENV-1, and 1–4 years
Figure 3. Age distribution of laboratory-positive cases, Puerto
Rico, 2010. A: Age distribution and rates of laboratory-positive cases;
B: Age distribution and incidence of RT-PCR-positive cases by infecting
DENV-type; C: Primary and secondary DENV infections by age group
from a representative sample of RT-PCR-positive cases; error bars
indicate standard error of the mean; denominators by age group are 15,
21, 73, 146, 162, 115, 74, 66, 54, 61 and 31, respectively.
doi:10.1371/journal.pntd.0002159.g003
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old were the only age group more frequently experiencing a
primary versus secondary DENV infection. Individuals infected
with DENV-1 were four times more likely to have a primary
infection than were those infected with DENV-2 or -4. A strength
of this investigation was utilization of multiple surveillance systems
to identify all reported suspect dengue cases. However, a minor
weakness was that data obtained from each system may not be
directly comparable due to different diagnostic algorithms used by
CDC-DB and private laboratories, and we were not able to
determine status of primary versus secondary infection or perform
sequencing on specimens from private laboratories. Because
private laboratories contributed ,5% of all laboratory-positive
dengue cases, this likely did not affect the conclusions of this
investigation.
The 2010 dengue epidemic was similar in several respects to the
1998 epidemic: both began in January during El Niño events
accompanied by above average temperatures, which while not a
determinant of epidemics in Puerto Rico [38] may contribute to
increased DENV transmission [39]; and both epidemics peaked in
week 32 of the calendar year and were predominated by
transmission of DENV-1 and -4 [19]. A notable difference was
that DENV-3 was essentially absent in 2010, whereas it accounted
for ,6% of cases during the 1998 epidemic [19]. DENV-3 was re-
introduced into Puerto Rico in 1998 following a 20-year absence
and was the predominant virus-type in the 2007 dengue epidemic
[20]. Thus, susceptibility to DENV-3 infection was likely high in
1998 and low in 2010, which likely explains these observations.
The American-African and Indonesian genotypes of DENV-1
and -4 have been circulating in Puerto Rico since introduced in
1978 and 1981, respectively [16,40]. However, the DENV-1
isolated in 2010 was distinct from the DENV-1 isolated during the
1998 epidemic (Fig. 4A and [41]) and was more closely related to
the DENV-1 isolated during the 2007 epidemic (Fig. 4A).
Similarly, the DENV-4 isolated during the 2010 epidemic was
distinct from the DENV-4 isolated in 1998 and was more closely
related to viruses circulating since 2004 (Fig. 4B). These findings
suggest that DENV-1 and -4 may have both experienced clade
replacements at some point after 1998 but prior to 2007. After the
re-introduction of DENV-3 into Puerto Rico in 1998, DENV-1
was not detected between 2001 and 2006 and DENV-4 was not
detected between 2000 and 2005 [42]. Nonetheless, apparent re-
introductions of DENV-1 in 2007 and DENV-4 in 2006 were soon
Table 1. Demographic and clinical characteristics of suspected dengue cases by diagnostic test result, Puerto Rico, 2010.
Suspected Laboratory-positive Laboratory-negative Laboratory-indeterminate
(N = 26,766 ) (N = 12,048) (N = 3,664) (N = 10,140)
Male, n (%) 14,332 (53.5) 6,628 (55.0) 1,858 (50.7) 5,364 (52.9)
Median age, years (range) 18 (5 days–102 years) 18 (1 month–102 years) 21 (1 week–90 years) 17 (5 days–100 years)
Hemorrhagic manifestation, n (%) 7,031 (26.3) 3,805 (31.5) 756 (20.6) 2,470 (24.4)
Dengue, n (%) 17,126 (64.0) 8,911 (74.0) 1,757 (48.0) 6,458 (63.7)
Dengue with warning signs, n (%) 10,836 (40.5) 5,991 (49.7) 1,100 (30.0) 3,745 (36.9)
Severe dengue, n (%) 2,680 (10.0) 1,334 (11.1) 393 (10.7) 953 (9.4)
DHF, n (%) 448 (1.7) 289 (2.4) 60 (1.6) 99 (1.0)
Death, n (%) 128 (0.5) 40 (0.3) 64 (1.7) 24 (0.2)
DHF = dengue hemorrhagic fever.
doi:10.1371/journal.pntd.0002159.t001
Table 2. Clinical characteristics of laboratory-positive cases by infecting dengue virus (DENV)-type, Puerto Rico, 2010.
DENV-1 DENV-2 DENV-4 DENV-1 vs. DENV-2 DENV-1 vs. DENV-4 DENV-2 vs. DENV-4
N = 5,126 N = 545 N = 1,757
n (%) n (%) n (%) RR 95% CI RR 95% CI RR 95% CI
Primary infection* 148 (28.5) 5 (6.8) 16 (7.5) 4.2 1.7–9.8 4.0 2.4–6.5 1.0 0.4–2.5
Hemorrhagic
manifestation
1,537 (30.0) 150 (27.5) 518 (29.5) 1.1 0.9–1.3 1.0 0.9–1.1 0.9 0.8–1.1
Dengue 4,151 (81.0) 442 (81.1) 1,457 (82.9) 1.0 1.0–1.0 1.0 1.0–1.0 1.0 0.9–1.0
Dengue with warning
signs
2,717 (53.0) 275 (50.5) 956 (54.4) 1.1 1.0–1.1 1.0 0.9–1.0 0.9 0.8–1.0
DHF 93 (1.8) 17 (3.1) 77 (4.4) 0.6 0.3–1.0 0.4 0.3–0.6 0.7 0.4–1.2
Severe dengue 434 (8.5) 55 (10.1) 250 (14.2) 0.8 0.6–1.1 0.6 0.5–0.7 0.7 0.5–0.9
Fatal dengue 21 (0.41) 5 (0.91) 10 (0.57) 0.4 0.2–1.2 0.7 0.3–1.5 1.6 0.6–4.7
Relative risk ratios (RR) were calculated with 95% confidence intervals (CI) for the indicated outcomes for case-patients infected with DENV-1, DENV-2, or DENV-4. Bolded
data indicate a significant risk in the indicated outcome associated with infection with the indicated DENV-type. DHF = dengue hemorrhagic fever.
*based on a sample of 818 RT-PCR-positive specimens that were tested for evidence of primary infection; denominators for DENV-1, -2 and -4 are 520, 73, and 225,
respectively.
doi:10.1371/journal.pntd.0002159.t002
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Figure 4. Maximum likelihood trees depicting the phylogenetic relationships of DENV-1, -2, and -4 isolated in Puerto Rico, 2010.
Each phylogeny was tested with 1,000 bootstrapping cycles. Each taxa label consists of country of origin (PR = Puerto Rico), year of virus isolation, and
GenBank accession number. Viruses isolated and sequenced for this investigation are labeled with a black dot. Genotype names were based on
previously published phylogenies [32,33]. All outgroups have been removed. A: Phylogenies were constructed using 29 DENV-1 E gene sequences:
seven from Puerto Rico in 2010, and 22 obtained from GenBank to represent the three main genotypes: American-African, South Pacific, and Asian. B:
Phylogenies were constructed using 24 DENV-2 E gene sequences: two from Puerto Rico in 2010, and 22 obtained from GenBank to represent the
three main genotypes: American-Asian, Cosmopolitan, and Asian II. C: Phylogenies were constructed using 26 DENV-4 E gene sequences: four from
Puerto Rico in 2010, and 22 obtained from GenBank to represent the two main genotypes: Indonesian and South East Asian.
doi:10.1371/journal.pntd.0002159.g004
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followed by the disappearance of DENV-3 in 2010 (this paper and
[42]). In place of the convenience sample used in this investigation
to describe the DENVs responsible for the epidemic, sequencing of
a representative sample of specimens and longitudinal sequence
analysis will be necessary to both confirm apparent clade
replacements and determine if other DENV clades contributed
to the 2010 epidemic.
Similar to previous epidemics in Puerto Rico (Table S1), 10–19
year olds were most affected during the 2010 epidemic; however,
unlike previous epidemics, 5–9 year olds were the next most
affected age group. The median age of individuals experiencing
secondary DENV infection declined from 27 years in 2007 [20] to
23 years in 2010, likely due to the relative proximity of the periods
of high infection pressure. Taken together, these observations
indicate an increase in incidence of dengue and a decrease in the
age of secondary infection, suggesting that the overall force of
DENV transmission may have been higher in 2010 than in
previous epidemic years.
The observation that DENV-2 and -4 cause relatively
infrequent clinical apparent illness upon primary DENV infection
is consistent with previous studies [43–48]. Similarly, our finding
that DENV-1 was a more frequent cause of clinically apparent
illness upon primary infection has also been previously reported
[43,49], including the observation of increased disease severity
during primary infection with DENV-1 compared to other
DENV-types [44,50,51]. Nonetheless, of 545 DENV-2 and
1,755 DENV-4 infections, roughly 7% were primary, indicating
that primary infection with these DENVs can cause clinically
apparent illness, contrary to previous assertions [46,47]. The
relative abundance of DENV-1 compared to DENV-2 and -4 is
unlikely to be responsible for the observed differences in likelihood
of causing clinically apparent illness upon primary infection, as
relative risk ratios compare the proportion of exposed individuals
experiencing the outcome of interest. This is supported by the
findings in the 1–4 year-old age group, of which ,80%
experienced a primary infection with DENV-1. Alternative
explanations for these observations include potential variations
in the sensitivity of detection of DENV-type-specific anti-DENV
IgG antibody and differences in force of infection between the
DENV-types circulating in 2010.
We also saw that DENV-1 and -2 were less frequently a cause of
severe dengue than DENV-4. This is in contrast to previous
studies where DENV-1 was a more frequent cause of DHF than
DENV-4 [52], and a study where DENV-2 was twice as likely to
result in DHF as DENV-4 [43]. Possible explanations for these
differences include: the comparatively small number of DENV-4
infections observed in previous studies; differences in clade and/or
viral fitness leading to differential pathogenicity [33,53,54]; and/
or the DENV-type(s) and sequence to which individuals were
previously exposed, which may affect the likelihood of developing
severe dengue [44,55,56].
This investigation had several limitations. First, because
individuals experiencing secondary infection may have a dimin-
ished anti-DENV IgM antibody response [57], suspected dengue
cases tested solely for anti-DENV IgM antibody may have been
misclassified. Second, although DENV is the sole flavivirus known
to cause clinically apparent illness in humans in Puerto Rico
(CDC, unpublished data), some proportion of anti-DENV IgM or
IgG positive results could have been due to infection with or
vaccination against another flavivirus [58], resulting in misclassi-
fication. Third, because clinical data was provided for .90% of
case-patients on only one occasion and some data variables were
incompletely reported (e.g. only 56% of suspected cases had a
reported status of hospitalization), severity of disease and the rates
of dengue with warning signs and severe dengue reported here
were likely underestimated. Finally, the description of the
epidemiology and molecular characteristics of dengue reported
here is only representative of reported, clinically apparent DENV
infections and may not be reflective of asymptomatic and sub-
clinical DENV infections.
The 2010 dengue epidemic in Puerto Rico demonstrated that
dengue continues to be a public health concern for Puerto Rico
residents and visitors, and surveillance systems and control
initiatives should continue to be supported and strengthened.
This epidemic also highlights the need for effective primary
prevention tools such as a dengue vaccine to reduce disease
morbidity and mortality.
Supporting Information
Table S1 Summary of epidemiologic data from previous dengue
epidemics in Puerto Rico.
(DOCX)
Figure S1 Flow diagram of data sources, diagnostic test results,
and sub-analyses of suspected dengue cases, Puerto Rico, 2010. A:
Data sources and diagnostic test results. B: Sub-analyses using RT-
PCR-positive specimens. PDSS = Passive Dengue Surveillance
System; PrivLab = private diagnostic laboratories; NDSS = Na-
tional Disease Surveillance System; EDSS = Enhanced Dengue
Surveillance System; IHC = immunohistochemistry; IgG ELI-
SA = anti-DENV immunoglobulin G enzyme-linked immunosor-
bent assay; RT-PCR = real-time reverse-transcriptase polymerase
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